Table 2.
Variable | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
OR | 95 % CI | p value | OR | 95 % CI | p value | |
Age | 1.046 | 1.015–1.078 | 0.004 | 1.071 | 1.029–1.114 | 0.001 |
Gender | ||||||
Male | Referent | Referent | ||||
Female | 0.644 | 0.363–1.146 | 0.134 | 0.462 | 0.216–0.985 | 0.046 |
BMI | 0.944 | 0.884–1.007 | 0.081 | 0.908 | 0.837–0.986 | 0.022 |
ASA score | ||||||
I and II | Referent | Referent | ||||
III and IV | 1.708 | 1.000–2.917 | 0.050 | 1.761 | 0.886–3.500 | 0.106 |
Hydronephrosis | 2.564 | 1.388–4.736 | 0.003 | 1.761 | 0.829–3.778 | 0.140 |
Reciept of NAC | 6.744 | 3.619–12.569 | <0.001 | 9.668 | 4.456–20.480 | <0.001 |
Prior heart attack | 1.058 | 0.506–2.213 | 0.881 | |||
Hypertonia | 0.845 | 0.507–1.410 | 0.521 | |||
Atrial fibrillation | 1.222 | 0.474–3.155 | 0.678 | |||
Asthma/COPD | 0.452 | 0.151–1.264 | 0.130 | |||
Diabetes mellitus | 1.088 | 0.499–2.374 | 0.832 | |||
cT | ||||||
cT2 | Referent | Referent | ||||
cT3 | 1.961 | 1.029–3.739 | 0.041 | 1.781 | 0.767–4.135 | 0.179 |
cT4 | 4.814 | 1.011–22.912 | 0.048 | 2.878 | 0.506–16.378 | 0.233 |
OR odds ratio, CI confidence interval, BMI body mass index, ASA American Society of Anesthesiologists, NAC neoadjuvant chemotherapy, COPD chronic obstructive pulmonary disease, cT clinical tumor stage